Biogen: Piper Sandler Raises PT to $225, Reiterates Overweight RatingPiper Sandler has raised its price target for Biogen Inc. (NASDAQ: BIIB) to $225 from $214, while maintaining its 'Overweight' rating, citing the company’s <a href="https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-biogen-stock-rating-on-acquisition-strength-4613329">enhanced growth outlook</a> following the acquisition of Apellis Pharmaceuticals’ key assets. The firm highlighted the strategic value of adding Empaveli and Syfovre to Biogen’s portfolio, which are expected to offset revenue declines from the company’s legacy multiple sclerosis treatments as exclusivity for those drugs wanes later this decade. Empaveli, used for rare kidney diseases, is anticipated to see strong adoption due to expanded approvals, while Syfovre, a treatment for geographic atrophy, is <a href="https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-biogen-stock-rating-on-acquisition-strength-4613329">expected to grow steadily</a> in an underpenetrated market.In addition, Biogen’s immunology pipeline, including the experimental therapy felzartamab, is seen as <a href="https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-biogen-stock-rating-on-acquisition-strength-4613329">a potential growth driver</a> for conditions with limited treatment options. Analysts also noted that the impact of declining royalties from Ocrevus, Biogen’s flagship MS drug, is expected to be mitigated by <a href="https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-biogen-stock-rating-on-acquisition-strength-4613329">newer formulations and contributions</a> from other therapies.Piper Sandler forecasts Biogen’s revenue to exceed $10.5 billion by 2027, with improved profitability and a <a href="https://www.investing.com/news/analyst-ratings/piper-sandler-upgrades-biogen-stock-rating-on-acquisition-strength-4613329">faster-than-expected reduction in debt</a> following the Apellis acquisition.
——————<h2>Output Instructions</h2>Process the entire article and return ONLY the formatted text with markdown citations, using the most appropriate citation style for each instance.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1c85e818776f0002.png" alt="Biogen: Piper Sandler Raises PT to $225, Reiterates Overweight Rating">

生化基因

Apellis

Biogen: Piper Sandler Raises PT to $225, Reiterates Overweight Rating

Biogen Inc. (NASDAQ: BIIB) fell approximately 2% in early trading on May 14, 2026, continuing a downward trend that has persisted since early February 2026. The stock, which reached a peak of around $202 in February, has since declined to roughly $172 as of early April 2026 <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>. This decline reflects broader concerns about the company's transition from its legacy multiple sclerosis (MS) portfolio to newer, high-potential therapies.The drop is not attributed to poor financial performance but rather to market impatience as Biogen navigates a strategic shift. While the company reported strong fourth-quarter results in February 2026, including revenue of $2.28 billion and adjusted earnings of $1.99 per share—both exceeding analyst expectations—the market has remained focused on the erosion of revenue from older MS drugs due to generic competition <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>. Additionally, a $34 million research and development charge in Q1 2026 has raised concerns about short-term earnings pressure <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>.Despite these challenges, Biogen's newer therapies, such as Leqembi for Alzheimer's and Skyclarys for rare neurological conditions, have shown promising growth, contributing $134 million and $133 million in revenue, respectively, in Q4 2025 <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>. The company's recent $5.6 billion acquisition of Apellis Pharmaceuticals is seen as a strategic move to bolster its immunology and rare disease offerings, with the potential to stabilize earnings by 2027 <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>.Analysts remain cautiously optimistic, with a 12% potential upside suggested by current price targets <a href="https://www.directorstalkinterviews.com/biogen-inc-biib-stock-analysis-potential-12-upside-amid-strong-buy-ratings/4121251099">according to analysis</a>. However, the stock's performance will likely hinge on the success of its new product launches and the integration of Apellis, as well as continued progress in its pipeline. Investors are advised to monitor the company's Q1 2026 earnings report, expected in early May, for further clarity on its path forward <a href="https://www.trefis.com/stock/biib/articles/595934/what-is-driving-biogens-recent-drop-and-what-comes-next/2026-04-07">according to analysis</a>.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1c848b4347af0002.png" alt="Biogen slips 2%">

Biogen

Biogen slips 2%

Apellis Pharmaceuticals has notified the trustee, paying agent, and holders of its 3.500% Convertible Senior Notes due 2026 of a supplemental indenture, fundamental change, and make-whole fundamental change. The supplemental indenture amends the original indenture dated September 16, 2019, between the company and U.S. Bank Trust Company, National Association. The change is related to the conversion of the notes and the payment of make-whole interest.Apellis Pharmaceuticals, Inc. has informed the trustee, paying agent, and holders of its 3.500% Convertible Senior Notes due 2026 of a supplemental indenture, a fundamental change, and a make-whole fundamental change. These notifications are in accordance with the terms of the original indenture dated September 16, 2019, between the company and U.S. Bank Trust Company, National Association. The amendments pertain to the conversion provisions of the notes and the payment of make-whole interest, which may affect the terms under which holders can convert their notes into shares of the company's common stock. The company has <a href="https://investors.apellis.com/static-files/39d3b5b5-1b98-416c-b16f-3f32bbd0b1c1">filed relevant disclosures with the Securities and Exchange Commission</a>, including Form 10-Q on May 7, 2026, and <a href="https://investors.biogen.com/static-files/c86f0725-0f55-45af-b0f1-7f7b459fffdf">additional filings related to the indenture amendments</a>. These updates are part of the company's ongoing compliance with its debt obligations and corporate governance requirements. Investors and note holders are advised to review the full disclosures for detailed terms and implications of the changes.

Apellis制药

Apellis Pharmaceuticals Announces Supplemental Indenture and Fundamental Change

• Biogen completes acquisition of Apellis Pharmaceuticals.
• Adds two commercialized products, EMPAVELI and SYFOVRE.
• Bolsters near-term growth outlook and expands into nephrology.
• Together, products recorded $689 million in net product revenue in 2025.
• Expected to be accretive to Biogen's non-GAAP diluted EPS in 2027.
• Strengthens Biogen's revenue and EPS growth potential.Biogen Inc. (Nasdaq: BIIB) has completed its acquisition of Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), marking a strategic expansion into nephrology and immunology. The transaction, valued at approximately $5.6 billion, includes a cash payment of $41 per share and a contingent value right (CVR) tied to future sales of SYFOVRE® <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">according to the announcement</a>. This acquisition adds two commercialized therapies—EMPAVELI® and SYFOVRE®—to Biogen's portfolio, both of which are <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">approved for rare and immune-mediated diseases</a>.EMPAVELI and SYFOVRE generated combined net product revenue of $689 million in 2025, with <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">expectations of mid-to-high teens growth through 2028</a>. The integration of these products is expected to enhance Biogen's near-term revenue outlook and provide long-term growth potential. The acquisition also <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">accelerates Biogen's entry into nephrology</a>, leveraging Apellis' commercial infrastructure and expertise.Financially, the deal is anticipated to be increasingly accretive to Biogen's non-GAAP diluted earnings per share (EPS) starting in 2027. The transaction is <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">expected to meaningfully increase Biogen's non-GAAP EPS CAGR</a> through the end of the decade. Biogen plans to finance the acquisition using a combination of cash and borrowings, with <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">a goal of fully deleveraging by the end of 2027</a>.The acquisition is subject to customary closing conditions and regulatory approvals, and Biogen <a href="https://investors.apellis.com/news-releases/news-release-details/biogen-acquire-apellis-enhancing-companys-growth-portfolio">expects to update its full-year 2026 guidance</a> when it reports first-quarter earnings.

Biogen completes Apellis acquisition, adds $689mln in net product revenue.

Bright Horizons Family Solutions and Remitly Global will join the S&P SmallCap 600 index on May 14, 2026, replacing Tri Pointe Homes and Apellis Pharmaceuticals, respectively. The changes are due to acquisitions by Sumitomo Forestry Group and Biogen Inc. The S&P SmallCap 600 is a stock market index that tracks the performance of small-cap companies in the US.<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-1c7bfab51c5ce002.png" alt="Remitly Global and Bright Horizons Join S&amp;P SmallCap 600, Tri Pointe Homes and Apellis Pharmaceuticals to be Replaced">

Bright Horizons

Remitly Global

Tri Pointe Homes

Remitly Global and Bright Horizons Join S&P SmallCap 600, Tri Pointe Homes and Apellis Pharmaceuticals to be Replaced

Catalyst<ul> <li>Recent RSI Overbought signals from May 1 to May 7 indicate strong bullish momentum for APLS.</li> <li>Analyst consensus includes one Buy and one Strong Buy rating, reflecting institutional optimism.</li> <li>Large and Extra-large fund flows show positive trends, suggesting institutional accumulation.</li></ul>Risk<ul> <li>A Marubozu White signal on May 7 points to biased bearish pressure, potentially reversing recent gains.</li> <li>At least one major firm maintains a Neutral rating, citing valuation concerns.</li></ul>

Key Factors

Biogen has completed its acquisition of Apellis Pharmaceuticals, integrating the commercial products EMPAVELI and SYFOVRE into its portfolio.Apellis Pharmaceuticals announced a supplemental indenture and fundamental change regarding its 3.500% Convertible Senior Notes due 2026.

APLS News